In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...

adrenal incidentalomas have become an important clinical entity for which pheochromocytoma must be considered, regardless of signs and symptoms. Third, knowledge of the relationship between ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Patients with optic disc edema are often brought to the attention of ophthalmologists either as referrals from internists or as a first consultation by a patient with visual symptoms. The ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

The role of chromogranin A in the assessment of surgical cure of pheochromocytoma was also investigated. The authors observed 21 consecutive patients who had pheochromocytomas at initial ...

A pheochromocytoma is a tumor that produces adrenaline ... Usually, it presents with no apparent signs or symptoms, unless the adrenal glands are producing excessive hormones (such as cortisol and ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date ...